Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641568 | 1.00 | TP53 (0.34) | TP53MAPTMEN1ALDH1A1GAA | |
| SCHEMBL22498297 | 0.90 | TP53 (0.36) | TP53MAPTMEN1ALDH1A1GAA | |
| SCHEMBL22498233 | 0.88 | MEN1 (0.32) | MEN1ALDH1A1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL29641596 | 0.88 | MEN1 (0.32) | MEN1ALDH1A1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL16783476 | 0.82 | HPGD (0.32) | TP53MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL22504997 | 0.81 | ALDH1A1 (0.32) | TP53MAPTMEN1ALDH1A1GAA | |
| SCHEMBL29641512 | 0.81 | ALDH1A1 (0.32) | TP53MAPTMEN1ALDH1A1GAA | |
| SCHEMBL22505053 | 0.77 | MEN1 (0.34) | TP53MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL16783447 | 0.75 | GABRP (0.43) | MEN1ALDH1A1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL22504968 | 0.75 | PIK3CD (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947384-B1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2023-11-01 | — | — | EP | disclosed |
| US-20220175784-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-09 | — | — | US | disclosed |
| WO-2020200918-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175784-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | PIKFYVE, PDPK1, PIK3R5 | TP53 1320/4885MAPT 2191/4885MEN1 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.